This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pacheco-Rodriguez, G. Articles by Moss, J. Search for Related Content PubMed PubMed Citation Articles by Pacheco-Rodriguez, G. Articles by Moss, J.

TSC2 Loss in Lymphangioleiomyomatosis Cells Correlated with Expression of CD44v6, a Molecular Determinant of Metastasis

¹ Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, NIH and ² Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland

Requests for reprints: Gustavo Pacheco-Rodriguez, Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, NIH, Building 10/Room 5N307, 9000 Rockville Pike, Bethesda, MD 20892-1434. Phone: 301-594-5705; Fax: 301-402-1610; E-mail: pachecog{at}nhlbi.nih.gov.

Lymphangioleiomyomatosis (LAM), a rare multisystem disease found primarily in women of childbearing age, is characterized by the proliferation of abnormal smooth muscle–like cells, LAM cells, that form nodules in the pulmonary interstitium. Proliferation of LAM cells results, in part, from dysfunction in tuberous sclerosis complex (TSC) genes TSC1 (hamartin) and/or TSC2 (tuberin). Identification of LAM cells in donor lungs, their isolation from blood, and their presence in urine, chylous ascites, and pleural effusions are consistent with their ability to metastasize. Here, we investigated the presence on LAM cells of the hyaluronic acid receptor CD44 and its splice variants associated with metastasis. The heterogeneous populations of cells grown from lungs of 12 LAM patients contain cells expressing mRNA for the variant CD44v6. Histologically, CD44v6 was present in LAM lung nodules, but not in normal vascular smooth muscle cells. CD44v6-positive sorted cells showed loss of heterozygosity at the TSC2 locus; binding of CD44v6 antibody resulted in loss of cell viability. Levels of CD44 were higher in cultured Eker rat (Tsc2–/–) cells than in Tsc2+/+ cells, but unlike human LAM cells, the Tsc2–/– Eker rat cells did not contain CD44v6 splice variant mRNA. CD44 splicing and signaling is regulated by osteopontin. Plasma from LAM patients contained higher concentrations of osteopontin than plasma of healthy, age-, and sex-matched volunteers (P = 0.00003) and may be a biomarker for LAM. The cell surface receptor CD44 and its splice variant CD44v6 may contribute to the metastatic potential of LAM cells. [Cancer Res 2007;67(21):10573–81]

This article has been cited by other articles:

				E. Lesma, S. M. Sirchia, S. Ancona, S. Carelli, S. Bosari, F. Ghelma, E. Montanari, A. M. Di Giulio, and A. Gorio The Methylation of the TSC2 Promoter Underlies the Abnormal Growth of TSC2 Angiomyolipoma-Derived Smooth Muscle Cells Am. J. Pathol., June 1, 2009; 174(6): 2150 - 2159. [Abstract] [Full Text] [PDF]

				C. G. Glasgow, N. A. Avila, J.-P. Lin, M. P. Stylianou, and J. Moss Serum Vascular Endothelial Growth Factor-D Levels in Patients With Lymphangioleiomyomatosis Reflect Lymphatic Involvement Chest, May 1, 2009; 135(5): 1293 - 1300. [Abstract] [Full Text] [PDF]

				G. Pacheco-Rodriguez, F. Kumaki, W. K. Steagall, Y. Zhang, Y. Ikeda, J.-P. Lin, E. M. Billings, and J. Moss Chemokine-Enhanced Chemotaxis of Lymphangioleiomyomatosis Cells with Mutations in the Tumor Suppressor TSC2 Gene J. Immunol., February 1, 2009; 182(3): 1270 - 1277. [Abstract] [Full Text] [PDF]

				S. Li, F. Takeuchi, J.-a. Wang, Q. Fan, T. Komurasaki, E. M. Billings, G. Pacheco-Rodriguez, J. Moss, and T. N. Darling Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas PNAS, March 4, 2008; 105(9): 3539 - 3544. [Abstract] [Full Text] [PDF]